Cohance Lifesciences Limited vs Vijaya Diagnostic Centre Limited
Last updated: 28 October 2026
MoneyDock presents a detailed comparison between two prominent players in India's healthcare sector: Cohance Lifesciences Limited (COHANCE.NS) and Vijaya Diagnostic Centre Limited (VIJAYA.NS). While Cohance Lifesciences operates in the broader life sciences domain, potentially encompassing pharmaceuticals, biotechnology, and research, Vijaya Diagnostic Centre is a well-established name in the diagnostic services industry, offering a wide array of tests and imaging services. Both companies cater to crucial healthcare needs, making them interesting subjects for investors looking to tap into India's growing healthcare expenditure. This analysis aims to provide a clear, data-driven perspective on their performance based on key financial metrics to help investors make informed decisions.
Key Metrics Comparison
| Metric | Cohance Lifesciences Limited | Vijaya Diagnostic Centre Limited |
|---|---|---|
| Current Price | ₹479.25 | ₹1442.70 |
| 52-Week High | ₹539.85 | ₹1570.70 |
| 52-Week Low | ₹279.90 | ₹861.40 |
| 1-Year Return | -10.99% | 44.67% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis
Based on the available metrics, a clear picture emerges for investors comparing Cohance Lifesciences and Vijaya Diagnostic Centre.
Returns: Vijaya Diagnostic Centre Limited significantly outperforms Cohance Lifesciences in terms of 1-Year Return. Vijaya has delivered a robust 44.67% return, indicating strong positive momentum and investor confidence over the past year. In stark contrast, Cohance Lifesciences has experienced a negative return of -10.99%, suggesting underperformance and potential headwinds during the same period. This metric alone points to Vijaya Diagnostic Centre as the clear winner for recent investor gains.
Price Stability and Range: Examining the 52-week high and low, both stocks exhibit considerable volatility. Cohance Lifesciences' current price of ₹479.25 is closer to its 52-week high of ₹539.85 than its 52-week low of ₹279.90, suggesting it has recovered somewhat from its lows, but still trades below its peak. Its range implies a significant swing capacity. Vijaya Diagnostic Centre, trading at ₹1442.70, is also closer to its 52-week high of ₹1570.70, demonstrating strong price action. However, its 52-week low of ₹861.40 reveals a substantial price fluctuation. While both have seen significant movement, Vijaya's current price maintains a stronger position relative to its recent peak compared to Cohance's trajectory from its peak.
Valuation: Unfortunately, critical valuation metrics like Trailing P/E and Market Cap are listed as 'N/A' for both companies. Without these figures, it is impossible to conduct a traditional valuation comparison. This absence means investors cannot currently assess whether either stock is trading at an attractive multiple of its earnings or understand the overall size and scale of these businesses from the provided data. This makes a direct valuation comparison challenging and highlights a data gap for comprehensive analysis.
Given the available data, Vijaya Diagnostic Centre shows superior performance in terms of recent returns and maintains a strong current price relative to its 52-week range. Cohance Lifesciences, on the other hand, has seen negative returns over the last year, indicating a less favorable short-term outlook based purely on price performance.
MoneyDock Verdict
For Aggressive Investors: Vijaya Diagnostic Centre Limited appears to be the more appealing option. Its impressive 1-Year Return of 44.67% indicates strong growth momentum, which aggressive investors typically seek. Cohance Lifesciences' negative return makes it a riskier bet for short-term, aggressive gains.
For Conservative Investors: Neither stock can be definitively recommended for conservative investors based on the limited data. The lack of P/E and Market Cap makes it difficult to assess fundamental value and stability. However, Cohance's negative return suggests higher risk, making Vijaya, despite its volatility, potentially less concerning given its positive performance.
For Long-Term SIP Investors: For long-term SIP investors, Vijaya Diagnostic Centre Limited, with its robust positive 1-Year Return, might present a better compounding opportunity. While both companies operate in promising healthcare sectors, Cohance's recent negative performance could signal underlying challenges that would need further investigation for a long-term commitment. Without valuation metrics, it's difficult to gauge if either is currently undervalued for long-term accumulation, but Vijaya's momentum is a positive sign.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.